Literature DB >> 11023518

Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.

Y Li1, M Bendandi, Y Deng, C Dunbar, N Munshi, S Jagannath, L W Kwak, H K Lyerly.   

Abstract

Immunoglobulin secreted by myeloma cells contains a unique antigenic determinant (idiotype [Id]) that may serve as a tumor-specific antigen. Although Id-protein-specific T-cell responses have been reported in patients with myeloma, it is not known whether primary myeloma tumor cells can present naturally processed Id peptides on their surface as a target. We immunized 2 healthy human stem-cell donors with Id proteins from their recipients. T cells from the immunized donors released high levels of T-helper 1-type cytokines in response to stimulation with myeloma cells from their recipients. The T-cell-mediated cytokine response to tumor cells was blocked by a major histocompatibility complex (MHC) class I monoclonal antibody, whereas the response to soluble Id protein was dependent on MHC class II. To investigate whether Id-specific CD8(+) T cells can recognize and kill autologous myeloma cells, we generated T cells from peripheral blood mononuclear cells from a third patient with myeloma by means of in vitro stimulation with autologous dendritic cells pulsed with Id protein. Tumor-specific lysis of myeloma cells was demonstrated by the lack of killing of autologous nonmalignant B cells or natural killer-sensitive K562 cells. Lysis of autologous myeloma targets was restricted by MHC class I molecules. These data represent the first report of class I-restricted T-cell recognition of fresh autologous myeloma targets and formally demonstrate that human myeloma cells can serve as targets of an Id-specific T-cell response. (Blood. 2000;96:2828-2833)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023518

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model.

Authors:  H R Galea; M Cogné
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 2.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

3.  In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Authors:  Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam Levitsky; Eduardo M Sotomayor
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

4.  Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Authors:  Jinsheng Weng; Soung-Chul Cha; Satoko Matsueda; Gheath Alatrash; Michael S Popescu; Qing Yi; Jeffrey J Molldrem; Michael Wang; Sattva S Neelapu; Larry W Kwak
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

5.  Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.

Authors:  M von Lilienfeld-Toal; J Nattermann; G Feldmann; E Sievers; S Frank; J Strehl; I G H Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

6.  Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

Authors:  Qing Yi; Susann Szmania; John Freeman; Jianfei Qian; Nancy A Rosen; Sanjaya Viswamitra; Michele Cottler-Fox; Bart Barlogie; Guido Tricot; Frits van Rhee
Journal:  Br J Haematol       Date:  2010-07-07       Impact factor: 6.998

7.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

8.  Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Authors:  Sebastian Belle; Fang Han; Maud Condomines; Olaf Christensen; Mathias Witzens-Harig; Bernd Kasper; Christian Kleist; Peter Terness; Marion Moos; Friedrich Cremer; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  Eur J Haematol       Date:  2008-03-19       Impact factor: 2.997

9.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Authors:  Paolo Serafini; Stephanie Mgebroff; Kimberly Noonan; Ivan Borrello
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Authors:  Sungyoul Hong; Jianfei Qian; Jing Yang; Haiyan Li; Larry W Kwak; Qing Yi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.